DISCLAIMER: This page is intended for members of the general public in United Kingdom - Great Britain only.
The information provided on this site is intended for general information and education for United Kingdom - Great Britain-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified Healthcare Professional.
Information about the Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)
This medicinal product has been granted full marketing authorisation for Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) for Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older.
If you have any questions or concerns regarding Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601), please speak to your doctor, nurse or Healthcare Professional.
Important information
For more information about the Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601), view the PDF file of the Product Information Leaflet.
Report a Side Effect
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Coronavirus Yellow Card reporting site https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store, and include the vaccine brand and batch/lot number, if available. By reporting side effects, you can help provide more information on the safety of this vaccine.
Contact Us
Tel: +44 203 5141838
09:00 - 17:00
Monday - Friday